We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DRUGMAKERS USING CHINESE FIRM'S APIs RISK PRODUCT DISAPPROVAL
DRUGMAKERS USING CHINESE FIRM'S APIs RISK PRODUCT DISAPPROVAL
March 3, 2004
Drug manufacturers using Shanghai Medical Ltd. as their source of active pharmaceutical ingredients (APIs) may have trouble getting new products approved by the FDA or imported into the U.S. following a warning letter that questioned the training of the firm’s quality staff, the validity of its records and its storage of reference standards.